Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark

The Phase 3 study with Favipiravir, sold under the brand name FabiFlu, by the company was conducted in 150 patients, it added.

published on : 23rd November 2020

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark Pharmaceuticals

Glenmark said that this was the second clinical study after the successful Favipiravir monotherapy trial earlier this year.

published on : 9th October 2020

Home treatment of Covid-19: Odisha issues SOP on use of Favipiravir tablet 

Rapid Response Teams at the district level will be specifically trained to assess the patients in home isolation.

published on : 3rd October 2020

'Don't prescribe Pirfenidone, Methylene blue': Centre issues FAQs to doctors on Covid-19 treatment

Interestingly, AIIMS discouraged the use of favipiravir, an antiviral that has been approved by the Drug Controller General of India for use in mild to moderate cases.

published on : 2nd September 2020

Brinton Pharmaceuticals gets DCGI nod to launch COVID-19 drug Favipiravir

With the launch of Faviton 400 mg, the number of tablets to be consumed have reduced to half, the statement said.

published on : 20th August 2020

Dr Reddy's launches Avigan (Favipiravir) for COVID-19 treatment

Dr Reddy's Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.

published on : 19th August 2020

Fusion Health Care launches COVID-19 drug Favipiravir and an immunity booster

The immunity booster consists of Vitamin C 1000 mg plus Zinc 10 mg, available in sugar free orange flavour, in a tube of 20 effervescent tablets.

published on : 17th August 2020

RLS gets approval to manufacture Favipiravir

RLS managing director Lohith Reddy said that Lupin, Hetero, Cipla, and Sun Pharma, have recently launched the oral pill under their own brand names at competitive prices.

published on : 11th August 2020

Glenmark to launch stronger version of FabiFlu for Covid-19 treatment in India

Though the number of tablets required in the new regimen will be reduced by half, it's not clear how much it will cost per patient.

published on : 6th August 2020

Another Hyderabad-based firm gets permit to produce COVID vaccine Favipiravir

Zenara Pharma is already in talks with institutions and hospitals to ensure quick availability of the product and improve patient coverage by providing it at discounted rates.

published on : 6th August 2020

Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet

'We can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India,' says Lupin President IRF Rajeev Sibal.

published on : 5th August 2020

Hetero Labs launches ‘Favivir’ at Rs 59 per tablet

The third company to do so, Hetero has made Favivir available at all retail medical and hospital pharmaceutical outlets from Wednesday.

published on : 30th July 2020

Hyd-based AVRA Labs develops new tech to reduce manufacturing cost of Favipiravir

Dr AV Rama Rao, founder of AVRA Pharmaceuticals, said: “The API, if it is imported from China, costs close to $2,000 per kg, which is about Rs 1.25 lakh.

published on : 27th July 2020

Jenburkt Pharma launches COVID-19 drug at Rs 39 per tablet

The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely solution.

published on : 24th July 2020

Cipla all set to launch Favipiravir drug for treatment of COVID patients: CSIR

An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild, moderate cases

published on : 23rd July 2020
1 2 >